Results 191 to 200 of about 31,215 (290)

Patients' Attitudes Towards Deprescribing Differ Across Specific Cardiovascular and Diabetes Medication: A Survey Study Assessing Within-Patient Differences. [PDF]

Basic Clin Pharmacol Toxicol
Stuijt PJC, Crutzen S, Heringa M, Hootsen JV, van Munster BC, Wildeboer AT, Taxis K, Denig P.   +7 more
europepmc   +1 more source

Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4314-4325, May 2026.
ABSTRACT Aims To compare the effects of individual SGLT2 inhibitors on preventing new‐onset proteinuria in patients with type 2 diabetes and preserved kidney function. Materials and Methods A target trial emulation was performed using commercially available databases, including health checkups and claims data, between April 1, 2014 and March 31, 2023 ...
Hiroki Nobayashi, Michihiro Satoh, Takuo Hirose, Shingo Nakayama, Yutaro Iwabe, Hideaki Hashimoto, Takahisa Murakami, Kouji Okada, Takefumi Mori, Hirohito Metoki   +9 more
wiley   +1 more source

Comparative cardiovascular risk of sulfonylureas with low- and high-affinities for cardiac mitochondrial adenosine triphosphate-sensitive potassium channels versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A cohort study. [PDF]

Diabetes Obes Metab
Chen MH, Lin LY, Hung TY, Lin TC, Li CY, Lin TH, Chen YH, Liou JT, Wang MT.   +8 more
europepmc   +1 more source

Glycemic control and renal function decline in patients with chronic coronary syndrome: A multicenter cohort study

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 791-800, May 2026.
Achieving HbA1c of 6.5–6.9% is associated with a reduced risk of renal complications in patients with diabetes and chronic coronary syndrome. Abstract Aims/Introduction Diabetes mellitus significantly contributes to renal complications, especially in patients with coronary artery disease (CAD).
An‐Yu Cheng, Chin‐Chou Huang, Hsin‐Bang Leu, Wei‐Hsian Yin, Wei‐Kung Tseng, Yen‐Wen Wu, Tsung‐Hsien Lin, Hung‐I Yeh, Kuan‐Cheng Chang, Ji‐Hung Wang, Chau‐Chung Wu, Jaw‐Wen Chen   +11 more
wiley   +1 more source

Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss. [PDF]

J Pharm Technol
Castellana E, Budau PM, Chiappetta MR.
europepmc   +1 more source

Evaluation of %CV and average glucose derived from pre‐ and postprandial 6‐point glucose measurements for assessing hypoglycemia risk

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 851-858, May 2026.
Six‐point pre‐ and postprandial glucose values were extracted from CGM to calculate average glucose and %CV. ROC analysis identified AG <167.7 mg/dL and %CV >21.6% as key risk factors, enabling simple detection of high hypoglycemia risk using limited glucose measurements. ABSTRACT Aims/Introduction This study determined the usefulness of coefficient of
Rika Soga, Keiichi Torimoto, Fumi Uemura, Yosuke Okada, Shingo Nakayamada   +4 more
wiley   +1 more source

Impact of renal function on antidiabetic drug selection in Japan: A real‐world analysis using the J‐DREAMS database

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 801-809, May 2026.
Using a large Japanese real‐world database, we examined antidiabetic drug selection in first and second therapy stratified by renal function and study period. The earlier initiation of SGLT2 inhibitors and GLP‐1 receptor agonists increased over time, particularly in second therapy, with prescribing patterns increasingly aligned across renal function ...
Masashi Kubota, Mitsuru Ohsugi, Kohjiro Ueki   +2 more
wiley   +1 more source

Correlation of Candida Species and Carriage in Uncontrolled and Controlled Diabetics on Various Oral Hypoglycemic Drug Regimen.

J Pharm Bioallied Sci
Upadhyay AK, Nathani D, Pandey R, Umbarkar AA, Sao K, Bhansali D, Shrivastava S.   +6 more
europepmc   +1 more source

Effects of intermittent fasting on HbA1c and weight in insulin versus oral hypoglycemic therapy-treated patients with type 2 diabetes mellitus: a systematic review and meta-analysis. [PDF]

Front Nutr
Al Qudah J, Beni ND, Ibrahim N, Khader S, Dempsey L, Butler AE.   +5 more
europepmc   +1 more source

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 766-780, May 2026.
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu, Ying Chun Lee, Yu‐Wei Fang, Wen‐Hui Hsieh, Ming‐Hsien Tsai   +4 more
wiley   +1 more source